Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 10.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,835 shares of the company’s stock after acquiring an additional 5,709 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.15% of Tarsus Pharmaceuticals worth $1,935,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Cowen AND Company LLC lifted its position in shares of Tarsus Pharmaceuticals by 3.5% in the 2nd quarter. Cowen AND Company LLC now owns 2,197,385 shares of the company’s stock worth $59,725,000 after buying an additional 74,855 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after buying an additional 698,712 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Tarsus Pharmaceuticals by 7.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock worth $37,536,000 after buying an additional 77,825 shares during the last quarter. Driehaus Capital Management LLC lifted its position in shares of Tarsus Pharmaceuticals by 126.1% in the 2nd quarter. Driehaus Capital Management LLC now owns 364,463 shares of the company’s stock worth $9,906,000 after buying an additional 203,300 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Tarsus Pharmaceuticals by 1,259.3% in the 2nd quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock worth $9,475,000 after buying an additional 322,942 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TARS has been the topic of a number of recent research reports. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. The Goldman Sachs Group lifted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Finally, Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $54.20.

Tarsus Pharmaceuticals Trading Up 2.8 %

Shares of NASDAQ:TARS opened at $52.50 on Monday. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $18.30 and a fifty-two week high of $54.44. The company has a market cap of $2.01 billion, a PE ratio of -13.78 and a beta of 1.04. The company’s 50-day moving average price is $44.72 and its 200 day moving average price is $34.37. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.